We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02978755
Recruitment Status : Completed
First Posted : December 1, 2016
Last Update Posted : April 6, 2022
Information provided by (Responsible Party):
GamaMabs Pharma

Brief Summary:
First in Human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor II) receptor. The primary objective of the study is to determine the GM102 recommended dose.

Condition or disease Intervention/treatment Phase
Neoplasm, Gynecologic Drug: GM102 Drug: GM102 escalating doses Phase 1

Detailed Description:

AMHRII, an embryonic receptor, is reexpressed in a subset of gynecological cancers. GM102 is a humanized low fucose monoclonal antibody with a high affinity to AMHRII receptor. GM102 acts through enhanced capability to engage immune effector cells (macrophages, natural killer (NK) cells) to trigger ADCC (antibody dependent cellular cytotoxicity) and phagocytosis of tumor cells.

Patients with gynecological tumors expressing AMHRII receptor on the tumor cells in archived tissue as determined prior to study entry will be eligible for C101 study.

C101 consists in a phase I part (dose and schedule escalation) and a phase Ib part (expansion).

The phase I part is designed to determine the recommended phase 2 dose (RP2D) using the classical 3+3 dose-finding design. In six successive escalating dose cohorts, patients will receive GM102 infusions every 2 weeks until progression or toxicity. In 4 additional cohorts, patients will receive GM102 infusions weekly until progression or toxicity and GM102 infusions combined with chemotherapy until progression or toxicity.

A Trial Steering Committee (TSC) will analyze and qualify the toxicities and will provide recommendations according to the dose administration rules defined in the protocol.

At the end of the phase I part, the RP2D will be determined, taking into account dose limiting toxicities (DLTs), overall toxicity, pharmacokinetics and pharmacodynamic effects of GM102.

The Phase Ib part of the study will confirm the tolerance of the selected dose (RP2D) and will assess antitumoral activity of GM102 in three parallel cohorts of patients with Sex Cord-Stromal tumors, and AMHRII positive ovarian and cervix cancers. Patients will be treated until progression or toxicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
  • phase 1 escalation GM102 single agent
  • phase 1 escalation GM102 combined with paclitaxel and carboplatin
  • phase 1b: 3 parallel expansion cohorts at the recommended dose of GM102 single agent
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open, Non Controlled, Multicenter, First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer
Study Start Date : June 2016
Actual Primary Completion Date : June 10, 2020
Actual Study Completion Date : June 10, 2020

Arm Intervention/treatment
Experimental: GM102 escalating doses
8 successive cohorts
Drug: GM102
GM102 escalating doses (phase1)

Experimental: GM102 escalating doses + carboplatin+paclitaxel
2 successive cohorts
Drug: GM102 escalating doses
GM102 escalating doses combined with paclitaxel and carboplatin

Experimental: GM102 recommended dose
3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
Drug: GM102
GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)

Primary Outcome Measures :
  1. Phase I part: incidence of Dose Limiting Toxicities (DLTs) [ Time Frame: Four weeks ]
    Number of patients in the DLT evaluable population experiencing at least one DLT

  2. Phase Ib part: incidence of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) at Recommended Phase 2 Dose (RP2D) [ Time Frame: Through study completion, an average of 1 year ]
    Number of patients with at least one AE

Secondary Outcome Measures :
  1. PK: Maximum Serum Concentration [Cmax] [ Time Frame: up to 16 weeks ]
    Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI

  2. PK: Area Under the Curve [AUC] [ Time Frame: up to 16 weeks ]
    Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI

  3. Response Rate using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 [ Time Frame: Through study completion ]
    Percentage of patients who achieved a Complete Response (CR) or a Partial Response (PR) based on RECIST version 1.1

  4. Clinical benefit rate [ Time Frame: up to 3 months ]
    Percentage of patients achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) superior to 3 months

  5. Duration of response [ Time Frame: Through study completion ]
    Duration of overall response in months for patients who achieved PR and/or CR

  6. Time to progression (TTP) [ Time Frame: Through study completion ]
    Time from first dose received until objective tumor progression

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced, or metastatic recurrent gynecological cancer, for whom no standard alternative therapy is available, having received at least one line of therapy and expressing AMHRII on tumor cells.
  • If possible at least one lesion should be identified for 2 biopsies: a baseline biopsy and an under-treatment biopsy for AMHRII expression and GM102 pharmacodynamics evaluation.
  • Available tumor block or at least 10 slides from formalin-fixed paraffin-embedded (FFPE) archival tissue.
  • At least one measurable lesion by RECIST (Response Evaluation Criteria in Solid Tumors) on screening CT-scan.
  • Written Informed Consent forms.
  • Willing and able to comply with the trial requirements.
  • Covered by healthcare insurance in accordance with local requirements.

For phase 1b, only patients with either Sex cord stromal tumors or epithelial ovarian cancer or cervix cancer will be eligible

Exclusion Criteria:

  • Age < 18 years old.
  • Eastern Cooperative Oncology Group (ECOG) performance status > 1
  • Life expectancy < 12 weeks.
  • Known or symptomatic brain metastasis (other than totally resected or previously irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.
  • Concurrent treatment with any other anticancer therapy.
  • Concurrent chronic corticosteroid treatment.
  • Known severe anaphylactic or other hypersensitivity reactions secondary to a prior exposure to human antibodies or to any protein product.
  • Washout period before treatment initiation: < 3 weeks or 5 times the half-life, whichever is shorter, for prior antitumor therapy (small molecules and/or antibody-drug conjugates, radiotherapy) or 6 weeks for monoclonal antibodies.
  • Any active concomitant malignancy.
  • Serious concomitant illness e.g. active infection requiring systemic antibiotic, antifungal or antiviral drug, or physical examination or laboratory abnormalities, that, in the opinion of the Investigator, would compromise protocol objectives.
  • Poor bone marrow reserve as defined by neutrophils < 1.0 x 10E9/L or haemoglobin < 9.0 g/dL or platelet count < 100 x 10E9/L.
  • Poor organ function as defined by any one of the following: left ventricular ejection fraction ≤ 40%, serum creatinine > 1.5 x upper limit of normal (ULN), total bilirubin > 1.5 x ULN, AST and ALT> 2.5 x ULN in the absence of liver metastasis or > 5 x ULN in case of documented liver metastasis.
  • Non-resolution of any prior treatment related toxicity to < Grade 2, except for alopecia according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.
  • Pregnancy or breastfeeding.
  • Patient with reproductive potential who do not agree to use an accepted effective method of contraception - investigator's judgment - during the study period and for at least 4 months following completion of study treatment.
  • Patient participating in another clinical trial investigating a treatment during the study and within 30 days prior to first study treatment administration.
  • Patient deprived of her liberty by a judicial or administrative decision, patient admitted to a hospital, social institution or who is under a measure of legal protection, patient hospitalized without consent or who is in an emergency situation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02978755

Layout table for location information
Institut Bordet
Brussels, Belgium, 1000
UZ Leuven
Leuven, Belgium
CHU Besançon
Besançon, France
Institut Bergonié
Bordeaux, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Institut de cancerologie de Montpellier
Montpellier, France
Institut de cancerologie de Lorraine
Nancy, France
Institut Curie
Paris, France
Institut Universitaire Cancer Toulouse - Oncopole
Toulouse, France
Gustave Roussy
Villejuif, France
United Kingdom
Royal Marsden Hospital
London, United Kingdom
Sponsors and Collaborators
GamaMabs Pharma
Layout table for investigator information
Principal Investigator: Alexandra Leary, MD/PhD Gustave Roussy center, Villejuif, France
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: GamaMabs Pharma
ClinicalTrials.gov Identifier: NCT02978755    
Other Study ID Numbers: C101
First Posted: December 1, 2016    Key Record Dates
Last Update Posted: April 6, 2022
Last Verified: March 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases